Literature DB >> 8242612

Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.

H Nakagomi1, M Petersson, I Magnusson, C Juhlin, M Matsuda, H Mellstedt, J L Taupin, E Vivier, P Anderson, R Kiessling.   

Abstract

An impaired immune response is frequently observed in cancer patients and tumor-bearing mice. T-cells from mice with an experimental colon carcinoma were recently shown to express T-cell receptors that completely lacked the signal-transducing molecule CD3 zeta. Here, we have investigated the expression of the signal-transducing molecule zeta on lymphocytes from 14 patients with colorectal carcinomas using flow cytometric analysis of permeabilized cells with a monoclonal antibody (TIA-2; IgG1) specific for the cytoplasmic domain of the zeta chain as well as with immunoprecipitation and analysis on diagonal gel electrophoresis. We demonstrate that T-cells isolated from the tumors of the patients express significantly less CD3 zeta than T-cells in the peripheral blood of the same patients and that the peripheral blood of the patients express decreased levels of zeta chains, as compared to the levels found in lymphocytes from healthy controls. This decreased expression was also observed on zeta chains associated with the low affinity Fc receptor for IgG found in tumor-infiltrating NK cells (Fc gamma RIIIA alpha; CD16).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242612

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  76 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis.

Authors:  E Matutes; E Coelho; M J Aguado; R Morilla; A Crawford; K Owusu-Ankomah; D Catovsky
Journal:  J Clin Pathol       Date:  1996-02       Impact factor: 3.411

3.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

4.  Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy.

Authors:  A H Zea; M T Ochoa; P Ghosh; D L Longo; W G Alvord; L Valderrama; R Falabella; L K Harvey; N Saravia; L H Moreno; A C Ochoa
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 5.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

6.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

Authors:  K Staveley-O'Carroll; E Sotomayor; J Montgomery; I Borrello; L Hwang; S Fein; D Pardoll; H Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

Review 7.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

8.  A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis.

Authors:  J Bylund; T Christophe; T Cristophe; F Boulay; A Romero; K Hellstrand; C Dahlgren
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

9.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 10.  IL-2 gene therapy of solid tumors: an approach for the prevention of signal transduction defects in T cells.

Authors:  K S Zier; B Gansbacher
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.